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HbA1c concentration in male interventional group is 
signifi cantly less than that of the control group.[7] We 
concluded that weekly vitamin D supplementation 
had benefi cial eﬀ ects on glycemic parameters in male 
T2DM patients.[6] Study regarding the glycemic control 
of vitamin D revealed diﬀ erent results. Recently, in 
a study conducted by Huang et al., the diﬀ erence in 
vitamin D levels between those with micro-and those 
with macro-albuminuria was examined.[7] They also 
aimed to determine whether low dose of cholecalciferol 
was able to ameliorate albuminuria. They conducted 
two investigations; a cross-sectional study of patients 
with T2DM and healthy controls and a longitudinal 
study on T2DM patients with albuminuria treated 
with conventional dose (800 IU) of cholecalciferol for 
6 months.[7] In the fi rst study, compared to controls and 
T2DM patients with normoalbuminuria, the serum 
25 (OH) D3 level was signifi cantly lower in patients 
with macro-albuminuria, but not in patients with micro-
albuminuria. They detected that plasma 25 (OH) D3 level 
was independently associated with micro-albuminuria. 
In their longitudinal investigation, they found that 
cholecalciferol eﬃ  ciently decreased micro-albuminuria 
in the early stages of treatment in conjunction with an 
increase in serum 25 (OH) D3 level.[7] They interpreted 
that conventional doses of cholecalciferol might have 
an anti-proteinuric eﬀ ect on Chinese T2DM patients 
with nephropathy.[7] Furthermore, they found that a 
low vitamin D status was more closely associated with 
micro-albuminuria in male subjects than in female 
ones.[7] Limitations of the study conducted by Heshmat 
et al. need to be considered, too. The sample size was 
small and the duration of drug therapy was short. 
Notably, the season may aﬀ ect vitamin D level and also 
may have an impact on the treatment outcome, a factor 
that is very diﬃ  cult to control.[7-10] In addition, the best 
eﬀ ective dose requires further investigation.[10-14] Lastly, 
the lack of assessment of parathormone level is a defi cit. 
There is an evidence revealing the positive association 
of parathyroid hormone and level of blood pressure 
as a perturbing factor for diabetic nephropathy.[2-9,15-18] 
Thus, the negative result on improving diabetes 
control and insulin resistance should not discourage 
its use. We suggest more prospective interventional 
investigations with longer duration with control of 
confounders to beĴ er detect this aspect of diabetic 
patients. Furthermore, it should be reminded that 
the most eﬀ ective dose of vitamin D requires further 
examination.
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Sir,
Diabetic kidney disease is a major risk of end-stage renal 
disease. Many complex factors are associated with the 
progression of diabetic nephropathy. Recently, much 
aĴ ention has been directed toward the role of vitamin D 
in the insulin resistance and treatment of diabetic 
nephropathy.[1] Heshmat et al., conducted a randomized 
double-blind clinical trial to find out the effect of 
vitamin D on insulin resistance and anthropometric 
parameters in type 2 diabetes mellitus (T2DM).[2] They 
included 42 diabetic patients with similar baseline 
characteristics in two groups; intervention group with 
single intramuscular injection of 300,000 IU of vitamin 
D3 and placebo group. In their study, 3 months aĞ er 
vitamin D injection, HbA1c, anthropometric factors, 
and homeostasis model assessment index in the 
intervention group remained constant while, serum 
25-hydroxy vitamin D3 (25 (OH) D3) significantly 
increased. They assumed that a single injection of 
vitamin D was not accompanied with improvement 
of diabetes control and insulin resistance.[2] It was 
suggested that vitamin D, was a negative regulator 
of the circulating and local tissue renin-angiotensin 
system, whereas the renin-angiotensin system has a 
signifi cant role in the physiology of sodium and volume 
homeostasis.[3-6] Excess activity of the renin-angiotensin 
system is associated with renal disease, diabetes, and 
high blood pressure.[3-6] Indeed, it is possible that the 
most important putative mechanisms associating 
vitamin D to control blood glucose are regulation 
of the renin-angiotensin system and suppression of 
renin biosynthesis.[2-5] Notably, the circulating and 
intra-pancreatic renin-angiotensin levels have been 
found to negatively influence β-cell function and 
peripheral insulin sensitivity.[2-7]. In agreement to 
this study, we conducted a double-blind randomized 
clinical trial on 60 T2DM patients who were divided 
into two groups with 30 patients in each. Serum 
25 (OH) D level was measured with ELISA method. 
Patients were given weekly vitamin D supplementation 
(50,000 units) for 12 weeks. In this investigation, 
there was no signifi cant relation between HbA1c and 
25 (OH) D levels prior the study. After treatment, 
25 (OH) D level in interventional group signifi cantly 
increased compared to that of the control group. The 
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